Neuropathic pain

Drug Safety Update

April 2022: Pregabalin (Lyrica): findings of safety study on risks during pregnancy

February 2021: Pregabalin (Lyrica): reports of severe respiratory depression

January 2021: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery

 April 2019: Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April

October 2017: Gabapentin (Neurontin): risk of severe respiratory depression

 December 2012: Carbamazepine, oxcarbazepine and eslicarbazepine potential risk of serious skin reactions

April 2008: Carbamazepine: genetic testing recommended in some Asian populations

  • Higher risk of carbamazepine-induced Stevens -Johnson syndrome in some Asian populations. Also see December 2012 update above

NICE Guidance

CG 173 Neuropathic pain in adults: pharmacological management in non-specialist settings

Local Guidance

See local trust neuropathic pain guidelines

See here for K&M ICB Controlled Drugs / Benzodiazepine Prescribing Patient Treatment Agreement

See here for the Kent and Medway ICB position statement on the prescribing of gabapentinoids for neuropathic pain

Other drugs which may also be used in the management of neuropathic pain are venlafaxine (unlicensed use), codeine,  buprenorphine and tramadol. Opioid analgesics are often of limited benefit.

Lidocaine Plasters

Kent and Medway Lidocaine Plaster Position Statement.

Lidocaine Plasters are NOT recommended for routine prescribing due to low clinical effectiveness and lack of robust evidence as per NHS England and NICE Guidelines.

Lidocaine Plasters should only be initiated on the advice or recommendation of a pain specialist for the licensed indication of post-herpetic neuralgia for those patients who have been treated in line with NICE [CG173] but are still experiencing neuropathic pain associated with previous herpes zoster infection. 

An individual management plan should be put in place for each patient specifying the duration of treatment, clear directions for reviews to take place and criteria outlining when prescribing should be continued or stopped.

Capsaicin 0.075% Cream

Capsaicin 0.075% cream is not recommended for prescribing in primary care due to limited evidence of benefit and significant cost impact. There is no licenced product available in the UK. For specialist use only within hospital pain services for defined patient cohorts.

Prescribers should not initiate or continue capsaicin in primary care. Patients requiring treatment should be referred to secondary care pain services.

Carbamazepine is used first line for the treatment of trigeminal neuralgia

Pack
28 tablet
500 tablet
56 tablet
84 tablet
Pack
100 tablet
28 tablet
500 tablet
56 tablet
84 tablet
Pack
250 ml
300 ml
50 ml
Pack
100 capsule
50 capsule
90 capsule
Pack
100 capsule
40 capsule
50 capsule
90 capsule
Pack
100 capsule
30 capsule
50 capsule
90 capsule
Pack
10 tablet
100 tablet
Pack
150 ml
Pack
100 capsule
14 capsule
56 capsule
84 capsule
Pack
21 capsule
56 capsule
84 capsule
Pack
100 capsule
14 capsule
56 capsule
Pack
21 capsule
56 capsule
84 capsule
Pack
100 capsule
14 capsule
56 capsule
Pack
84 capsule (12 x 7 capsules)
Pack
56 capsule (8 x 7 capsules)
Pack
56 capsule
Pack
473 ml
500 ml

On pain team advice only

Pack
250 tablet
28 tablet
Pack
28 tablet (2 x 14 tablets)

On pain team advice only

Pack
100 tablet
30 tablet
Pack
100 tablet
30 tablet (3 x 10 tablets)

On pain team/pain specialist advice only

Licensed for post-herpetic neuralgia only - see prescribing notes above

Pack
10 plaster
30 plaster

Capsaicin 0.075% cream is not recommended for prescribing in primary care due to limited evidence of benefit and significant cost impact. There is no licenced product available in the UK. For specialist use only within hospital pain services for defined patient cohorts.

Prescribers should not initiate or continue capsaicin in primary care. Patients requiring treatment should be referred to secondary care pain services.

Pack
45 gram
Pack
1 patch

Approved for peripheral nerve neurolysis in chronic pain management - Pain Clinic use only

Restricted to use where all standard neuropathic agents (oral and topical) have failed, or are inappropriate due to adverse effects or contra-indications.

Pack
1 ampoule
10 ampoule
  • On Formulary Preferred
  • On Formulary Second Line
  • On Formulary Third Line
  • Specialist Initiation
  • Secondary Care Only
  • Not Approved for Formulary